PDF herunterladen
Zeitschrift für Phytotherapie 2014; 35(05): 210-214
DOI: 10.1055/s-0034-1371742
Forschung
Nephrologie
© Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Phytotherapie bei Glomerulonephritis und weiteren zur Niereninsuffizienz führenden Nierenerkrankungen – Teil 2[ * ]

Rainer Nowack
Verantwortlicher Herausgeber dieser Rubrik:
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. Oktober 2014 (online)

    Lizenzen und Reprints

Zusammenfassung

Im ersten Teil dieser Reihe wurde in die autoimmunologische Pathogenese der Glomerulonephritiden und ihre immunsuppressive Standardtherapie eingeführt. Nach Astragalus membranaceus werden diesmal mit Angelica sinensis und Tripterygium wilfordii zwei weitere TCM-Drogen vorgestellt, die in China verbreitet bei Nierenkrankheiten eingesetzt werden. Extrakte von Tripterygium und die isolierte Reinsubstanz Triptolid sind in Tiermodellen und beim Menschen bei Nierenerkrankungen in vielversprechender Weise wirksam, bei Fehldosierung jedoch hochtoxisch. Ihr Potenzial könnte erst nach weiterer intensiver Forschung zur Therapie dieser Erkrankungen genutzt werden.

Summary

Phytotherapy for glomerulonephritis and related kidney diseases. Part 2

The first part of this series introduced the autoimmune pathogenesis of glomerulonephritis and its standard immunosuppressive therapy. Besides Astragalus membranaceus, two other TCM drugs, Angelica sinensis and Tripterygium wilfordii, are widely used in China in the treatment of renal diseases. Both are presented in this current review. However, extracts of Tripterygium wilfordii and the isolated pure substance triptolide are effective in animal models and in humans with kidney disease but highly toxic when doses are administered incorrectly. Their potential could be used only after further intensive research in the treatment of these diseases.

Schlüsselwörter

Glomerulonephritis - Angelica sinensis - Tripterygium wilfordii - Triptolid

Key words

Glomerulonephritis - Angelica sinensis - Tripterygium wilfordii - triptolide

* Teil 1 (Übersicht über die klinische Forschung und Astragalus membranaceus) ist in Heft 1/2014 erschienen.


 

  • Literatur

  • 1 Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy 1999; 19: 870-876
    CrossrefPubMedGoogle Scholar
  • 2 Wang H, Li J, Yu L et al. Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis. Life Sci 2004; 74: 1645-1658
    CrossrefPubMedGoogle Scholar
  • 3 Wojcikowski K, Wohlmuth H, Johnson DW, Gobe G. Effect of Astragalus membranaceus and Angelica sinensis combined with Enalapril in rats with obstructive uropathy. Phytother Res 2010; 24: 875-884
    PubMedGoogle Scholar
  • 4 Song J, Meng L, Li S et al. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, improved renal microvascular insufficiency in 5/6 nephrectomized rats. Vascul Pharmacol 2009; 50: 185-193
    CrossrefPubMedGoogle Scholar
  • 5 Bensky D, Gamble A. Chinese Herbal Medicine: Materia Medica. Seattle: Eastland Press; 1993
    Google Scholar
  • 6 Gu WZ, Chen R, Brandwein S et al. Isolation, purification, and characterization of immunosuppressive compounds from Tripterygium: triptolide and tripdiolide. Int J Immunopharmacol 1995; 17: 351-356
    CrossrefPubMedGoogle Scholar
  • 7 Ni H, Zhao W, Kong X et al. Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclear factorkappa B activation. Acta Haematol 2014; 131: 102-111
    CrossrefPubMedGoogle Scholar
  • 8 Ma PC, Lu XY, Yang JJ, Zheng QT. 16-Hydroxytriptolide, a new active diterpene isolated from Tripterygium wilfordii . Yao Xue Xue Bao 1991; 26: 759-763
    PubMedGoogle Scholar
  • 9 Kupchan SM, Court WA, Dailey Jr RG et al. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii . J Am Chem Soc 1972; 94: 7194-7195
    CrossrefPubMedGoogle Scholar
  • 10 Owa C, Messina Jr ME, Halaby R. Triptolide induces lysosomal-mediated programmed cell death in MCF-7 breast cancer cells. Int J Womens Health 2013; 5: 557-569
    PubMedGoogle Scholar
  • 11 Rousalova I, Banerjee S, Sangwan V et al. Minnelide: A novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo. PLoS One 2013; 8: e77411
    CrossrefPubMedGoogle Scholar
  • 12 Chen K, Shi Q, Kashiwada Y et al. Anti-aids agents, 6. Salaspermic acid, an anti-HIV principle from Tripterygium wilfordii, and the structure-activity correlation with its related compounds. J Nat Prod 1992; 55: 340-346
    CrossrefPubMedGoogle Scholar
  • 13 Matta R, Wang X, Ge H et al. Triptolide induces anti-inflammatory cellular responses. Am J Transl Res 2009; 1: 267-282
    PubMedGoogle Scholar
  • 14 Lin N, Sato T, Ito A. Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f. suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts. Arthritis Rheum 2001; 44: 2193-2200
    CrossrefPubMedGoogle Scholar
  • 15 Tao X, Schulze-Koops H, Ma L et al. Effects of Tripterygium wilfordii Hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum 1998; 41: 130-138
    CrossrefPubMedGoogle Scholar
  • 16 Lin N, Liu C, Xiao C et al. Triptolide, a diterpenoid triepoxide, suppresses inflammation and cartilage destruction in collagen-induced arthritis mice. Biochem Pharmacol 2007; 73: 136-146
    CrossrefPubMedGoogle Scholar
  • 17 Dai CS, Liu ZH, Chen HP et al. Combined treatment of triptolide and emodin inhibits the progressions of anti-GBM nephritis in rats. Chin J Nephrol Dial Transplant 2000; 9: 117-123
    PubMedGoogle Scholar
  • 18 Zheng CX, Chen ZH, Zeng CH et al. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int 2008; 74: 596-612
    CrossrefPubMedGoogle Scholar
  • 19 Ma R, Liu L, Liu X et al. Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy. Exp Ther Med 2013; 6: 649-656
    PubMedGoogle Scholar
  • 20 Wan YG, Sun W, Zhen YJ et al. Multi-glycoside of Tripterygium wilfordii Hook. f. reduces proteinuria through improving podocyte slit diaphragm dysfunction in anti-Thy1.1 glomerulonephritis. J Ethnopharmacol 2011; 136: 322-333
    CrossrefPubMedGoogle Scholar
  • 21 Tao X, Fan F, Hoffmann V et al. Effective therapy for nephritis in (NZB x NZW)F1 mice with triptolide and tripdiolide, the principal active components of the Chinese herbal remedy Tripterygium wilfordii Hook F. Arthritis Rheum 2008; 58: 1774-1783
    CrossrefPubMedGoogle Scholar
  • 22 Dong K, Li LS, Yang JW et al. Effect of Tripterygium wilfordii Hook F on acute renal rejection in rats. Chin J Nephrol Dial Transplant 1993; 2: 369-373
    PubMedGoogle Scholar
  • 23 Yang Y, Liu Z, Tolosa E et al. Triptolide induces apoptosis death of T lymphocyte. Immunopharmacology 1998; 40: 139-149
    CrossrefPubMedGoogle Scholar
  • 24 Li H, Liu ZH, Dai CS et al. Triptolide inhibits proinflammatory factor-induced over-expression of class MHC and B7 molecules in renal tubular epithelial cells. Acta Pharmacol Sin 2002; 23: 775-781
    PubMedGoogle Scholar
  • 25 Hong Y, Zhou W, Li K, Sacks SH. Triptolide is a potent suppressant of C3, CD40 and B7 expression in activated human proximal tubular epithelial cells. Kidney Int 2002; 62: 1291-1300
    CrossrefPubMedGoogle Scholar
  • 26 Leuenroth SJ, Okuhara D, Shotwell JD et al. Triptolide is a traditional Chinese medicinederived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 2007; 104: 4389-4394
    CrossrefPubMedGoogle Scholar
  • 27 Chen D, Ma Y, Wang X et al. Triptolide-containing formulation in patients with autosomal dominant polycystic kidney disease and proteinuria: an uncontrolled trial. Am J Kidney Dis 2014; 63: 1070-1072
    CrossrefPubMedGoogle Scholar
  • 28 Hu WX, Tong Z, Yao XD et al. Double dosage of Tripterygium wilfordii Hook F in treating the nephritic syndrome: a prospective clinical trial. Chin J Nephrol Dial Transplant 1997; 6: 210-214
    PubMedGoogle Scholar
  • 29 Rong S, Hu WX, Liu ZH et al. A new regimen of Tripterygium wilfordii Hook F in treating primary mesangial proliferative glomerulonephritis. Chin J Nephrol Dial Transplant 1998; 7: 409-414
    PubMedGoogle Scholar
  • 30 Qin WZ, Liu CH, Yang SM. Tripterygium wilfordii Hook F in systemic lupus erythematosus. Clin Med J (Engl) 1981; 94: 827-830
    PubMedGoogle Scholar
  • 31 Wang QW, Li LS, Zhang JH, Yu YS. Clinical study of triptolide in the treatment of IgA nephropathy. Jiangsu Medicine Drug 1991; 17: 7-10
    PubMedGoogle Scholar
  • 32 Chen Y, Gong Z, Chen X et al. Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome. Cochrane Database Syst Rev 2013; 8 CD008568
    PubMedGoogle Scholar
  • 33 Chen YZ, Gao Q, Zhao XZ et al. Meta-analysis of Tripterygium wilfordii Hook F in the immunosuppressive treatment of IgA nephropathy. Intern Med 2010; 49: 2049-2055
    CrossrefPubMedGoogle Scholar
  • 34 Zhu B, Wang Y, Jardine MJ et al. Tripterygium for the treatment of chronic kidney disease: A systemic review and meta-analysis. Renal & Metabolic Division, University of Sydney, Sydney, Australia; Department of Nephrology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang, China; Department of Nephrology, Peking University First Hospital, Beijing, China. [Abstract]. Congress of the American Society of Nephrology 2012, San Diego
    PubMedGoogle Scholar
  • 35 Ge Y, Xie H, Li S et al. Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial. J Transl Med 2013; 11: 134
    CrossrefPubMedGoogle Scholar
  • 36 Ji SM, Wang QW, Yin G et al. Clinical trial of Tripterygium wilfordii Hook F in human kidney transplantation. Chin J Nephrol Dial Transplant 1998; 7: 415-420
    PubMedGoogle Scholar
  • 37 Tao X, Younger J, Fan FZ et al. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a doubleblind, placebo-controlled study. Arthritis Rheum 2002; 46: 1735-1743
    CrossrefPubMedGoogle Scholar
  • 38 Cibere J, Deng Z, Lin Y et al. A randomized double blind, placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: reanalysis using logistic regression analysis. J Rheumatol 2003; 30: 465-467
    PubMedGoogle Scholar
  • 39 Goldbach-Mansky R, Wilson M, Fleischmann R et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med 2009; 151: 229-240
    CrossrefPubMedGoogle Scholar
  • 40 Han R, Rostami-Yazdi M et al. Triptolide in the treatment of psoriasis and other immune- mediated inflammatory diseases. Br J Clin Pharmacol 2012; 74: 424-436
    CrossrefPubMedGoogle Scholar
  • 41 Mak DH, Schober WD, Chen W et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 2009; 8: 2509-2516
    CrossrefPubMedGoogle Scholar
  • 42 Lue Y, Sinha Hikim AP, Wang C et al. Triptolide: a potential male contraceptive. J Androl 1998; 19: 479-486
    PubMedGoogle Scholar